Genome Biologics news

Genome Biologics secures up to €9.8M in equity funding from the EIC Accelerator to accelerate development of its clinical programs for the prevention of cardiotoxicity and heart damage – an area of huge unmet need within the EU and globally

Genome Biologics UG, Frankfurt, Germany, today announced that they have been awarded up to 9.8 million euros of equity funding through the European Innovation Council (EIC) Accelerator program to accelerate their breakthrough innovations in cardiovascular drug discovery and development.

Cardiovascular diseases account for the majority of mortality and disability globally, accounting for 32% of all global deaths. Over €100 bn euros, or 50% of the total European h

Dec. 19, 2021